Surgery today · 2025
Association of visceral fat with unresectable/recurrent gastric cancer patients following chemotherapy: a propensity score-matched analysis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nishiguchi Ryohei, Shimakawa Takeshi, Asaka Shinichi, Ogawa Masako, Sagawa Masano, Kuhara Kotaro, Usui Takebumi, Yokomizo Hajime, Shiozawa Shunichi
Аннотация
PURPOSE: To clarify the association between visceral fat and the prognosis in patients with unresectable or recurrent gastric cancer following chemotherapy.
METHODS: A total of 118 patients were retrospectively analyzed and categorized into high- and low-visceral fat index (VFI) groups, using a cutoff value of 46.5 cm2/m2. Propensity score matching was performed to adjust for background factors. The overall survival (OS) and progression-free survival (PFS) were compared between the groups. In addition, the objective response rate (ORR), disease control rate (DCR), nutritional indicators, chemotherapy duration, transition rates, and adverse effects were analyzed. A multivariate analysis was used to identify the predictors of the OS and PFS.
RESULTS: After matching, the high-VFI group demonstrated a significantly better OS and PFS than the low-VFI group. The ORR (40.6% vs. 15.6%, P = 0.026) and DCR (90.6% vs. 67.7%, P = 0.025) were significantly higher in the high-VFI group than the low-VFI group. The high-VFI group also showed a better nutritional status, longer S-1-based chemotherapy duration, higher transition rates to second-/third-line therapy, and fewer adverse events than the low-VFI group. A multivariate analysis identified VFI loss and target lesions (peritoneal and liver) as independent predictors of the OS, whereas VFI loss and target/non-target lesions were predictors of the PFS.
CONCLUSION: A high VFI was associated with an improved survival in patients with unresectable or recurrent gastric cancer by enhancing chemotherapy tolerance, reducing adverse events, and increasing the ORR and DCR.
METHODS: A total of 118 patients were retrospectively analyzed and categorized into high- and low-visceral fat index (VFI) groups, using a cutoff value of 46.5 cm2/m2. Propensity score matching was performed to adjust for background factors. The overall survival (OS) and progression-free survival (PFS) were compared between the groups. In addition, the objective response rate (ORR), disease control rate (DCR), nutritional indicators, chemotherapy duration, transition rates, and adverse effects were analyzed. A multivariate analysis was used to identify the predictors of the OS and PFS.
RESULTS: After matching, the high-VFI group demonstrated a significantly better OS and PFS than the low-VFI group. The ORR (40.6% vs. 15.6%, P = 0.026) and DCR (90.6% vs. 67.7%, P = 0.025) were significantly higher in the high-VFI group than the low-VFI group. The high-VFI group also showed a better nutritional status, longer S-1-based chemotherapy duration, higher transition rates to second-/third-line therapy, and fewer adverse events than the low-VFI group. A multivariate analysis identified VFI loss and target lesions (peritoneal and liver) as independent predictors of the OS, whereas VFI loss and target/non-target lesions were predictors of the PFS.
CONCLUSION: A high VFI was associated with an improved survival in patients with unresectable or recurrent gastric cancer by enhancing chemotherapy tolerance, reducing adverse events, and increasing the ORR and DCR.